Search Results
391 results found-
Answers to the most frequently asked questions about Clinical Trials.
https://www.csl.com/research-and-development/clinical-studies/clinical-studies-faqs -
There are a lot of important things to think about before deciding to participate in a trial.
https://www.csl.com/research-and-development/clinical-studies/how-to-participate -
CSL's clinical trials are one of the most important steps in the years-long process of obtaining approval for new medications.
https://www.csl.com/research-and-development/clinical-studies -
CSL conducts clinical trials on all of its products. See if one of our current clinical trials might be right for you.
https://www.csl.com/research-and-development/clinical-studies/current-clinical-trials -
CSL conducts clinical trials in accordance with our Code of Conduct and the current Guideline for Good Clinical Practice (GCP) of the International Conference on Harmonization (ICH).
https://www.csl.com/research-and-development/clinical-studies/research-practices -
Saving lives and protecting health sits at the center of our purpose as a business.
https://www.csl.com/sustainability/healthier-communities/patient-experience -
The guidelines also highlight FILSPARI as the only therapy with proven efficacy compared to optimized RASi in clinical trials — with more patients enrolled in PROTECT than in all prior RASi trials combined.
https://newsroom.csl.com/2025-09-26-CSL-Vifor-and-Travere-Therapeutics-Recognize-Updated-KDIGO-Clinical-Practice-Guidelines-for-IgA-Nephropathy -
Nephrology and Clinical Immunology at the University Hospital, RWTH Aachen, Germany, and steering committee member for the PROTECT clinical trial.
https://newsroom.csl.com/2024-04-24-CSL-Vifor-and-Travere-Therapeutics-Announce-European-Commission-approves-FILSPARI-R-sparsentan-for-the-treatment-of-IgA-Nephropathy -
QURE), and sponsorship of the clinical trials transitioned to CSL after it acquired global rights to commercialize the treatment.
https://newsroom.csl.com/2022-11-22-U-S-Food-and-Drug-Administration-approves-CSLs-HEMGENIX-R-etranacogene-dezaparvovec-drlb-,-the-first-gene-therapy-for-hemophilia-B